Thermo Fisher ScientificNYSE: TMO

Biognosys' Spectronaut®, a top software for DIA proteomics that works with various vendors, is now available for purchase through Thermo Fisher Scientific due to a new reselling agreement. Customers can access both Thermo Scientific mass spectrometry systems and Biognosys' Spectronaut software in one package offered by Thermo Fisher. This announcement was made on September 18, 2024, highlighting Biognosys' role as a key provider of software for analyzing mass spectrometry-based proteomics data.

Thermo Fisher Scientific (NYSE:TMO) will be participating in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 5, 2024, at 8:30 AM ET. The company will be represented by Marc Casper, who is the Chairman, President, and CEO. Tejas Savant from Morgan Stanley will also be part of the conference call.

Thermo Fisher (TMO) shared its earnings report 30 days ago. What can we expect for the stock moving forward?

Thermo Fisher (TMO) is looking positive due to its strong partnerships and successful product launches.

Thermo Fisher Scientific is a leading stock for dividend growth, but it faces a complicated situation after the pandemic. Recent earnings indicate strong growth in important areas, even though the company's valuation is high. Their focus on research and development, along with acquisitions, sets TMO up for ongoing success in the future.

Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.

Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.

Thermo Fisher on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials.

The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.